Business
Medicenna Updates On-Going Phase 2b Clinical Trial Protocol for Recurrent Glioblastoma
Medicenna Updates On-Going Phase 2b Clinical Trial Protocol for Recurrent Glioblastoma ...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Updates On-Going Phase 2b Clinical Trial Protocol for Recurrent Glioblastoma\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, Sept. 28, 2017\n\n\n\nSafety Review Committee Reports Encouraging Drug Distribution and Tolerability\n\n\n\nTORONTO and HOUSTON, Sept. 28, 2017 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA), a clinical stage immuno-oncology company, announced today that based on encouraging drug distribution and safety data observed in the on-going Phase 2b clinical trial of MDNA55 for the treatment of patients with recurrent glioblastoma (rGBM), the Company has commenced implementation of an updated protocol following its submission to the U.S. Food and Drug Administration (FDA) and approval by the respective Institutional Review Boards (IRBs). The amended protocol incorporates an enhanced drug delivery procedure which will be used for the treatment of the remaining patients. The updated protocol includes higher doses and volumes of MDNA55 as well as an increase in the total expected study size – from 43 patients under the original protocol to 52 total planned patients now expected to enroll. Patient enrolment and treatment continues at multiple sites.\n\n\"Based on data that will be presented at the 2017 CNS conference in Boston (7-11 October 2017), we are pleased with the encouraging drug distribution, safety and tolerability of MDNA55 in our ongoing Phase 2b rGBM study,\" stated Dr. Fahar Merchant, Chairman, President and CEO of Medicenna. \"These data indicate a wider therapeutic window than originally anticipated and we can leverage this new, preliminary safety understanding for the remainder of the study. The decision to amend the study protocol by increasing the dosage and volume of MDNA55 has the potential to address the needs of an expanded patient population, including patients with larger or multi-focal tumors.\" \n\nThis protocol amendment was based on a planned safety analysis following a unanimous recommendation...